Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M J Reike; M A Ingersoll; D C Müller; T C M Zuiverloon; T Strandgaard; A M Kamat; S B Williams; R Seiler; T Todenhöfer; L Dyrskjøt; R Nawroth; P Goebell; B Schmitz-Dräger; J P Sfakianos; J Meeks; A Horowitz; P C Black

doi:10.1016/j.urolonc.2022.09.012

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Urol Oncol. 2023 May;41(5):211-218. doi: 10.1016/j.urolonc.2022.09.012. Epub 2022 Oct 18.

Authors

M J Reike¹, M A Ingersoll², D C Müller³, T C M Zuiverloon⁴, T Strandgaard⁵, A M Kamat⁶, S B Williams⁷, R Seiler⁸, T Todenhöfer⁹, L Dyrskjøt⁵, R Nawroth¹⁰, P Goebell¹¹, B Schmitz-Dräger¹², J P Sfakianos¹³, J Meeks¹⁴, A Horowitz¹⁵, P C Black¹⁶

Affiliations

¹ Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
² Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France; Mucosal Inflammation and Immunity group, Department of Immunology, Institut Pasteur, Paris, France.
³ Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
⁴ Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
⁵ Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁶ Department of Urology, Division of Surgery, MD Anderson Cancer Center, The University of Texas, Houston, TX.
⁷ Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston.
⁸ Klinik für Urologie, Spitalzentrum Biel, Biel, Schweiz.
⁹ Clinical Trials Unit, Studienpraxis Urologie, Nürtingen, Germany.
¹⁰ Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
¹¹ Department of Urologic and Pediatric Urology, University Clinic Erlangen, Erlangen, Germany.
¹² Department of Urologic and Pediatric Urology, University Clinic Erlangen, Erlangen, Germany; Urologie 24, Nürnberg, Germany.
¹³ Department of Urology, Icahn School of Medicine at Mount Sinai, NY.
¹⁴ Department of Urology, Northwestern University School of Medicine, Chicago, IL.
¹⁵ Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY.
¹⁶ Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: pblack@mail.ubc.ca.

PMID: 36266219
DOI: 10.1016/j.urolonc.2022.09.012

Abstract

Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

Keywords: Bacillus Calmette-Guerin (BCG); Bladder cancer; Immunotherapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine / therapeutic use
Biology
Humans
Immunotherapy
Neoplasm Invasiveness
Neoplasm Recurrence, Local / drug therapy
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy

Substances

Adjuvants, Immunologic
BCG Vaccine